IDH1 and central nervous system cancer: Moreover, in IDH1 mutation/1p19q intact gliomas subjected to TCGA, there was increase tendency of copy number loss with WHO grade (4.3%, 10.7% and 25.0% in grade 2, 3, and 4, respectively).